GenoLogics will use the grant for product development for future clinical applications and new desktop sequencing systems and to expand sales and marketing functions.

GenoLogics’ laboratory information management system (LIMS) software is designed for next-generation genomics labs.

Earlier this year, both the companies have entered into a co-selling agreement for the GenoLogics LIMS.

GenoLogics CEO Michael Ball said the strategic investment by Illumina illustrates their companies’ collective commitment to help their customers overcome some of the challenging barriers to next-generation sequencing adoption, namely data management.

"Illumina provides important insights to these challenges and we look forward to working jointly with them as we expand our line of LIMS products for next-generation genomics," Ball said.